Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
NEJM Evidence · 28.03.2023 · 2 (4)
DOI: 10.1056/evidoa2200239 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 28.03.2023. Verfasst von Georgina V Long und 19 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney.
- Dana-Farber Cancer Institute, Boston.
- Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore.
- Department of Dermatology, University Hospital Essen, Essen, Germany.
- German Cancer Consortium, Partner Site Essen, Essen, Germany.
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
Zitieren
APA
Long, G. V., Stephen Hodi, F., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., Janoski De Menezes, J., Dalle, S., Arance, A., Grob, J. J., Keidel, S., Shaikh, A., Sobiesk, A. M., Dolfi, S., & Tawbi, H. A. (2023). Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence, 2(4). https://doi.org/10.1056/evidoa2200239
Vancouver
Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence. 2023;2(4). doi:10.1056/evidoa2200239
BibTeX
@article{Long2023,
author = {Long, Georgina V and Stephen Hodi, F and Lipson, Evan J and Schadendorf, Dirk and Ascierto, Paolo A and Matamala, Luis and Salman, Pamela and Castillo Gutiérrez, Erika and Rutkowski, Piotr and Gogas, Helen J and Lao, Christopher D and Janoski De Menezes, Juliana and Dalle, Stéphane and Arance, Ana and Grob, Jean-Jacques and Keidel, Sarah and Shaikh, Anadil and Sobiesk, Anne Marie and Dolfi, Sonia and Tawbi, Hussein A},
title = {Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma},
journal = {NEJM Evidence},
year = {2023},
volume = {2},
number = {4},
doi = {10.1056/evidoa2200239}
}
EUVIMED